Drug Trial Radar · NCT04064840
GnRH Agonist for Dual Trigger in IVF and for Luteal Phase Support in FET
Last checked: Nov 20, 2026Latest source record: May 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
784
Planned (sponsor's estimate)
Start
Sep 1, 2019
Primary completion
Sep 1, 2024
Study completion May 30, 2026
Sponsor
- Lead sponsor
- The University of Hong KongAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Aug 22, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years, up to 42 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objectives of this study are to compare the efficacy of the dual trigger group vs the hCG trigger group on the live birth rate in women undergoing IVF and the efficacy of the agonist in LP group vs the placebo group on the live birth rate in women undergoing FET.
Conditions
- Subfertility
Interventions
IVF: Decapeptyl and hCGDrug
When at least three follicles reach 18 mm in diameter, recombinant hCG 0.25mg and decapeptyl 0.2mg will be injected subcutaneously.
FET: DecapeptylDrug
On the day of FET, decapeptyl 0.1 mg will be injected subcutaneously.
IVF: hCG and normal salineDrug
When at least three follicles reach 18 mm in diameter, recombinant hCG 0.25mg and normal saline will be injected subcutaneously.
FET: Normal SalineDrug
On the day of FET, normal saline will be injected subcutaneously.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Live birth rateTime frame: after 22 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Department of Obstetrics and Gynaecology
Hong Kong, Hong Kong, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.